MedTrace Logo

Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma

NCT01849783 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2022-05-11

Study results available
· View outcomes & findings →

Summary

This phase II trial investigates whether patients greater than or equal to 65 years of age diagnosed with myeloma or another plasma cell malignancy will have better outcomes with transplant followed by maintenance therapy, as primarily measured by progression-free survival, versus non-transplant approaches.

Conditions

  • Extramedullary Plasmacytoma
  • Isolated Plasmacytoma of Bone
  • Light Chain Deposition Disease
  • Primary Systemic Amyloidosis
  • Stage I Multiple Myeloma
  • Stage II Multiple Myeloma
  • Stage III Multiple Myeloma

Interventions

DRUG

dexamethasone

Given PO

DRUG

cisplatin

Given IV

DRUG

doxorubicin

Given IV

DRUG

cyclophosphamide

Given IV or PO

DRUG

etoposide

Given IV

DRUG

bortezomib

Given IV

DRUG

thalidomide

Given PO

DRUG

melphalan

Given IV

PROCEDURE

autologous stem cell transplant

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Margarida Magalhaes-Silverman

    lead OTHER

Principal Investigators

  • Margarida Magalhaes-Silverman, MD · University of Iowa

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
65 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-04
Primary Completion
2020-09-30
Completion
2020-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01849783 on ClinicalTrials.gov